Home' Australian Pharmacist : Australian Pharmacist October 2015 Contents Australian Pharmacist October 2015 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month
(15,500 pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than
10,000 pharmacists – a typical monthly article receives 3000 plus
assessments, with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Answers for crossword on page 73.
Across: 1. Macrosomia, 3. Placenta,
6. Obesity, 7. Diet, 9. Lifestyle, 12. Fetus,
13. Insulin, 14. Pancreas, 15. Neonate.
Down: 1. Maternal, 2. Thrush, 4. Adverse,
5. Intolerance, 8. Polydipsia, 10. Fasting,
Viekira Pak and Viekira
The all-oral, direct-acting antiviral Viekira
Pak and Viekira Pak-RBV (ombitasvir/
paritaprevir/ritonavir tablets; dasabuvir
tablets with or without RBV) has been
approved by the Therapeutic Goods
Administration (TGA)1,2 and recommended
by the Pharmaceutical Benefits Advisory
Committee for patients with genotype 1
(GT1) chronic hepatitis C virus (HCV)
infection, Abbvie has announced.
The therapies are approved by the TGA for
use by people with genotype 1 chronic
hepatitis C virus infection, including those
with compensated liver cirrhosis.
Viekira Pak is an interferon-free therapy
that combines three direct-acting antivirals
with distinct mechanisms to target
separate stages of the disease lifecycle
to inhibit the virus from reproducing.
Taken with or without ribavirin, the all-oral
therapy have shown high SVR cure* rates
and low rates of treatment discontinuation
due to adverse events (1.2%) in clinical
The recommended oral dose of Viekira Pak
is two paritaprevir/ritonavir/ombitasvir
(75/50/12.5 mg) tablets once daily
(morning) and one dasabuvir (250 mg)
tablet twice daily (morning and evening)
with food. Viekira Pak with RBV is used in
GT1 HCV patients with compensated liver
cirrhosis and GT1a HCV patients without
cirrhosis. The recommended dose of RBV
is taken twice daily and depends on a
patient’s body weight (<75 kg = 1000 mg
and ≥75 kg = 1200 mg).
Treatment duration is usually 12 weeks,
but for patients with GT1a HCV infection
with compensated liver cirrhosis who
have had a previous null response to
pegylated interferon and ribavirin,
24 weeks is recommended.
*‘Cure’ defined as ≤25 IU/mL HCV RNA 12 weeks post
1. AbbVie. Viekira Pak Australian Product Information 2015.
2. AbbVie. Viekira Pak RBV Australian Product Information 2015.
FLO, which specialises in the management
of nasal and sinus conditions, has
rebranded its extended Family Range.
There are more than 14 product SKUs
in the range. The company has kept
some brand heritage while introducing
more distinct, impactful packaging and
labelling to help pharmacy staff and
The FLO Family Range caters for all ages,
can be administered at any angle and
takes only 2–3 seconds using a fine
mist spray or gentle dropper applicator.
The products are preservative-free and
include essential minerals to help promote
healing within the nasal passages.
The isotonic saline formulations also
closely mimic the body’s own natural
tissue fluids,providing gentle and
Links Archive Australian Pharmacist September 2015 Australian Pharmacist November 2015 Navigation Previous Page Next Page